Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
10.3760/cma.j.issn.0253-2727.2018.07.005
- Author:
Shan Hao TANG
1
;
Ying LU
;
Pi Sheng ZHANG
;
Xu Hui LIU
;
Xiao Hong DU
;
Dong CHEN
;
Ke Ya SHA
;
Shuang Yue LI
;
Jun Jie CAO
;
Lie Guang CHEN
;
Xian Xu ZHUANG
;
Ren Zhi PEI
;
Xiao Wen TANG
Author Information
1. Department of Hematology, Yinzhou People Hospital, Ningbo 315040, China.
- Publication Type:Journal Article
- Keywords:
DNMT3A R882 mutation;
FLT3-ITD mutation;
Hematopoietic stem cell transplantation;
Leukemia, myeloid, acute
- MeSH:
Adolescent;
Adult;
Child;
Child, Preschool;
DNA (Cytosine-5-)-Methyltransferases/genetics*;
DNA Methyltransferase 3A;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute;
Male;
Middle Aged;
Mutation;
Nucleophosmin;
Prognosis;
Retrospective Studies;
Young Adult;
fms-Like Tyrosine Kinase 3/genetics*
- From:
Chinese Journal of Hematology
2018;39(7):552-557
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the impact of FLT3-ITD and DNMT3A R882 double mutations to the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: FLT3-ITD, DNMT3A, C-kit, CEBPA, FLT3-TKD and NPM1 mutations were detected in 206 newly diagnosed AML patients by Sanger sequencing (M(3) and those received FLT3 inhibitor were excluded). Clinical data of AML patients were retrospectively analyzed to compare the prognosis of each gene mutation group. Results: ①Of 206 patients, 104 were male and 102 female with a median age of 38 (3-63) years, including 6 cases of M(0), 24 cases of M(1), 56 cases of M(2), 39 cases of M(4), 63 cases of M(5), 6 cases of M(6) and 12 unclassified cases. ②All 206 patients were divided into four groups according to the mutation gene at the time of diagnosis: FLT3-ITD(+) DNMT3A R882(+) group (group A), FLT3-ITD(+) DNMT3A R882(-) group (group B), FLT3-ITD(-) DNMT3A R882(+) group (group C) and FLT3-ITD(-) DNMT3A R882(-) groups (group D). Gender, leukocyte count at diagnosis, chromosome karyotype, the median age, FAB classification, disease status prior to transplantation, type of donor, conditioning regimen and GVHD were not significantly different between four groups (P>0.05). ③The 2-year cumulative recurrence rate (CIR) of group A was significantly higher than that of other groups [group A (72.2±2.6)%, group B (38.6±0.6)%, group C (36.8±1.6)%, group D (27.8±0.1)%, respectively, P<0.05], while the 2-year overall survival (OS) rate and 2-year leukocyte-free survival (LFS) rate were lower than those of other groups [group A (30.9±13.3)%, (11.3±10.2)%; group B (67.5±7.8)%, (47.9±8.4)%; group C (61.4±12.4)%, (56.8±12.5)%; group D (80.1±3.7)%, (79.7±3.6)%, respectively, P<0.05]. Conclusion: AML patients with FLT3-ITD and DNMT3A R882 double mutations had a very high CIR and low OS, LFS after transplantation.
